Pharmaceutical
Technology
Health
Perrigo
$46.779876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$46.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.48 (-1.02%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Perrigo and other stocks, options, ETFs, and crypto commission-free!
About
PERRIGO COMPANY PLC, also called Perrigo, is a healthcare company, which engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals. Read More The Consumer Healthcare Americas segment comprises the U.S., Mexico and Canada consumer healthcare business. The Consumer Healthcare International segment includes branded consumer healthcare business primarily in Europe and consumer focused businesses in the U.K., Australia, and Israel. The Prescription Pharmaceuticals refers to the U.S. prescription pharmaceuticals business. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.
Employees
10,600
Headquarters
Dublin, Dublin
Founded
1887
Market Cap
6.42B
Price-Earnings Ratio
49.99
Dividend Yield
1.96
Average Volume
1.46M
High Today
$47.22
Low Today
$46.39
Open Price
$46.91
Volume
271.88K
52 Week High
$84.94
52 Week Low
$36.28
Collections
Pharmaceutical
Technology
Health
Healthcare
Europe (Non-UK)
Europe
News
Yahoo FinanceMar 21
Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update
Company met all milestones in 2018 and this year expects to report Phase III top-line results for Epsolay® and TWIN, potentially best-in-class papulopustular rosacea and acne vulgaris topical medications Recent approval of Perrigo's generic acyclovir cream, 5%, has already provided revenue during the first quarter of 2019 NESS ZIONA, Israel, March 21, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, devel...
Markets InsiderMar 20
Perrigo Appoints Ray Silcock As CFO
(RTTNews) - Perrigo Company plc (PRGO) Wednesday said it has appointed Ray Silcock as Executive Vice President and Chief Financial Officer, effective March 25, 2019. Ray will lead the global finance, tax, internal audit, investor relations, corporate communications, business development and treasury functions. He will report to President and Chief Executive Officer, Murray Kessler. Silcock joins Perrigo having been CFO of both public and private equity held companies for over 20 years. Most recently, he w...
PR NewswireMar 20
Perrigo Appoints Seasoned CPG Veteran Ray Silcock As Chief Financial Officer
DUBLIN, March 20, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ray Silcock will join the Company as Executive Vice President and Chief Financial Officer, effective March 25, 2019. Ray will lead the global finance, tax, internal audit, investor relations, corporate communications, business development and treasury functions.
Price Paid on Robinhood
29% Lower
Right Now
52 Week Low
$36.28
Average Price Paid
$66.07
52 Week High
$84.94
Earnings
$0.93
$1.08
$1.24
$1.39
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours